Aaron S Kesselheim (Aaron Kesselheim)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 72

Top Topics

Drug Administration

Muscular Dystrophy

Health Insurance

Peripheral Artery Disease

Top Venues

Annals of internal medicine

Clinical pharmacology and therapeutics

The New England journal of medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Iselin Dahlen Syversen, Kevin Schulman, Aaron S Kesselheim, William B Feldman
A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders. The Milbank quarterly (2024)
Caroline Horrow, Aaron S Kesselheim
Regulating Laboratory Tests: What Framework Would Best Support Safety and Validity? The Milbank quarterly (2024)
William B Feldman, Leah Zoe Gibson Rand, Daniel Carpenter, Massimiliano Russo, Anushka Bhaskar, Zhigang Lu, Eric G Campbell, Jonathan Darrow, Aaron S Kesselheim
Trust in the Food and Drug Administration: A National Survey Study. Clinical pharmacology and therapeutics 116 (2) (2024)
William B Feldman, Aaron S Kesselheim, Jerry Avorn, Massimiliano Russo, Shirley V Wang
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease. Annals of internal medicine 177 (1) (2024)
Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label. Annals of internal medicine 177 (6) (2024)
Matthew Vogel, Benjamin N Rome, Aaron S Kesselheim, William B Feldman
Medicare Negotiation's Drug Reformulation Problem. Annals of internal medicine 177 (6) (2024)
Ameet Sarpatwari, Zhigang Lu, Massimiliano Russo, Heidi Zakoul, Su Been Lee, Gita A Toyserkani, Esther H Zhou, Cynthia LaCivita, Katherine Hyatt Hawkins Shaw, Laura Zendel, Gerald J Dal Pan, Aaron S Kesselheim
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians. Clinical pharmacology and therapeutics (2024)
Edward Robert Scheffer Cliff, David A Russler-Germain, C Joseph Ross Daval, Aaron S Kesselheim
US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
William B Feldman, Leah Zoe Gibson Rand, Daniel Carpenter, Massimiliano Russo, Anushka Bhaskar, Zhigang Lu, Eric G Campbell, Jonathan Darrow, Aaron S Kesselheim
Trust in the Food and Drug Administration: A National Survey Study. Clinical pharmacology and therapeutics 116 (2) (2024)
Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label. Annals of internal medicine (2024)
William B Feldman, Leah Zoe Gibson Rand, Daniel Carpenter, Massimiliano Russo, Anushka Bhaskar, Zhigang Lu, Eric G Campbell, Jonathan Darrow, Aaron S Kesselheim
Trust in the Food and Drug Administration: A National Survey Study. Clinical pharmacology and therapeutics (2024)
William B Feldman, Aaron S Kesselheim, Jerry Avorn, Massimiliano Russo, Shirley V Wang
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease. Annals of internal medicine 177 (1) (2024)
Matthew Vogel, Benjamin N Rome, Aaron S Kesselheim, William B Feldman
Medicare Negotiation's Drug Reformulation Problem. Annals of internal medicine 177 (6) (2024)
Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label. Annals of internal medicine 177 (6) (2024)
William B Feldman, Leah Zoe Gibson Rand, Daniel Carpenter, Massimiliano Russo, Anushka Bhaskar, Zhigang Lu, Eric G Campbell, Jonathan Darrow, Aaron S Kesselheim
Trust in the Food and Drug Administration: A National Survey Study. Clinical pharmacology and therapeutics 116 (2) (2024)
Ameet Sarpatwari, Zhigang Lu, Massimiliano Russo, Heidi Zakoul, Su Been Lee, Gita A Toyserkani, Esther H Zhou, Cynthia LaCivita, Katherine Hyatt Hawkins Shaw, Laura Zendel, Gerald J Dal Pan, Aaron S Kesselheim
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians. Clinical pharmacology and therapeutics 115 (6) (2024)
Matthew Vogel, Benjamin N Rome, Aaron S Kesselheim, William B Feldman
Medicare Negotiation's Drug Reformulation Problem. Annals of internal medicine (2024)
Stephanie Wang, Georg Hahn, Aaron S Kesselheim
Impact of Priority Review Voucher Eligibility on Research and Development of Medical Countermeasures. Clinical pharmacology and therapeutics (2024)
Kerstin N Vokinger, Jerry Avorn, Aaron S Kesselheim
Sources of Innovation in Gene Therapies - Approaches to Achieving Affordable Prices. The New England journal of medicine 388 (4) (2023)
Anders Olsen, Reed F Beall, Ryan P Knox, S Sean Tu, Aaron S Kesselheim, William B Feldman
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019. PLoS medicine 20 (11) (2023)
Kerstin N Vokinger, Miquel Serra-Burriel, Camille E G Glaus, Ulrich-Peter Rohr, Thomas J Hwang, Simon Andreas Dalla Torre di Sanguinetto, Aaron S Kesselheim
Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020. Annals of internal medicine 176 (10) (2023)
Liam Bendicksen, Diana M Zuckerman, Jerry Avorn, Sophia Phillips, Aaron S Kesselheim
The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence. Annals of internal medicine (2023)
Matthew Vogel, Aaron S Kesselheim, William B Feldman, Benjamin N Rome
Will Medicare Price Negotiation Delay Cancer-Drug Launches? The New England journal of medicine (2023)
Kerstin N Vokinger, Jerry Avorn, Aaron S Kesselheim
Sources of Innovation in Gene Therapies - Approaches to Achieving Affordable Prices. The New England journal of medicine 388 (4) (2023)
Kerstin N Vokinger, Jerry Avorn, Aaron S Kesselheim
Sources of Innovation in Gene Therapies - Approaches to Achieving Affordable Prices. The New England journal of medicine 388 (4) (2023)
Edward Robert Scheffer Cliff, Aaron S Kesselheim, William B Feldman
Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Beatrice L Brown, Aaron S Kesselheim, Ameet Sarpatwari
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures. PLoS medicine 20 (3) (2023)
Alexander Chaitoff, Aaron S Kesselheim
Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease. Circulation 148 (24) (2023)
Catherine S Hwang, Aaron S Kesselheim, Ameet Sarpatwari, Krista F Huybrechts, Gregory Brill, Benjamin N Rome
Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022 : An Interrupted Time-Series Analysis. Annals of internal medicine (2023)
Beatrice L Brown, Aaron S Kesselheim, Ameet Sarpatwari
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures. PLoS medicine 20 (3) (2023)
Kerstin N Vokinger, Jerry Avorn, Aaron S Kesselheim
Sources of Innovation in Gene Therapies - Approaches to Achieving Affordable Prices. The New England journal of medicine (2023)
Edward Robert Scheffer Cliff, Amar H Kelkar, David A Russler-Germain, Frazer A Tessema, Adam J N Raymakers, William B Feldman, Aaron S Kesselheim
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 43 (2023)
Sanket S Dhruva, Aaron S Kesselheim, Steven Woloshin, Robin Z Ji, Zhigang Lu, Jonathan J Darrow, Rita F Redberg
Physician Perspectives on FDA's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease. Clinical pharmacology and therapeutics (2023)
Beatrice L Brown, Aaron S Kesselheim, Ameet Sarpatwari
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures. PLoS medicine 20 (3) (2023)
Kerstin N Vokinger, Jerry Avorn, Aaron S Kesselheim
Sources of Innovation in Gene Therapies - Approaches to Achieving Affordable Prices. The New England journal of medicine 388 (4) (2023)
Leigh K Sharpless, Aaron S Kesselheim, Serena Laura Orr, Jonathan J Darrow
Variation in Endpoints in FDA Medication Approvals: A Review of Acute and Preventive Migraine Medications. Neurology (2023)
S Sean Tu, Aaron S Kesselheim
Preserving Timely Generic Drug Competition with Legislation on "Skinny Labeling". Clinical pharmacology and therapeutics (2023)
William B Feldman, Aaron S Kesselheim, Jerry Avorn, Massimiliano Russo, Shirley V Wang
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease. Annals of internal medicine (2023)
John C Messinger, Leo Beletsky, Aaron S Kesselheim, Rachel E Barenie
Moving Naloxone Over the Counter Is Necessary but Not Sufficient. Annals of internal medicine (2023)
Tahir Amin, Aaron S Kesselheim
A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness. Inquiry : a journal of medical care organization, provision and financing 59 (2022)
Leah Zoe Gibson Rand, Aaron S Kesselheim
Limitations on the Capability of the FDA to Advise. The American journal of bioethics : AJOB 22 (10) (2022)
Bryan S Walsh, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome
Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (10) (2022)
Leah Zoe Gibson Rand, G J Melendez-Torres, Aaron S Kesselheim
Alternatives to the quality-adjusted life year: How well do they address common criticisms? Health services research (2022)
Leah Zoe Gibson Rand, G J Melendez-Torres, Aaron S Kesselheim
Alternatives to the quality-adjusted life year: How well do they address common criticisms? Health services research 58 (2) (2022)
Hussain S Lalani, Aaron S Kesselheim, Benjamin N Rome
Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures? Annals of internal medicine 175 (6) (2022)
Erin C Fuse Brown, Aaron S Kesselheim, Debra Malina, Genevra Pittman, Stephen Morrissey
Fundamentals of Health Law - A New Perspective Series. The New England journal of medicine 387 (4) (2022)
Osman Moneer, Beatrice L Brown, Jerry Avorn, Jonathan J Darrow, Mayookha Mitra-Majumdar, Krysten W Joyce, Murray Ross, Catherine Pham, Aaron S Kesselheim
New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence. Drug safety 45 (4) (2022)
Thomas J Hwang, Aaron S Kesselheim, Ariadna Tibau, ChangWon C Lee, Kerstin N Vokinger
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO oncology practice 18 (9) (2022)
Alfred B Engelberg, Jerry Avorn, Aaron S Kesselheim
A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights. The New England journal of medicine 386 (12) (2022)
Mayookha Mitra-Majumdar, John H Powers, Beatrice L Brown, Aaron S Kesselheim
Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs. BMJ medicine 1 (1) (2022)
Leah Zoe Gibson Rand, G J Melendez-Torres, Aaron S Kesselheim
Alternatives to the quality-adjusted life year: How well do they address common criticisms? Health services research 58 (2) (2022)
Leah Zoe Gibson Rand, Aaron S Kesselheim
Performance-Linked Reimbursement and the Uncertainty of Novel Drugs. Circulation. Cardiovascular quality and outcomes 15 (1) (2022)
Mayookha Mitra-Majumdar, John H Powers, Beatrice L Brown, Aaron S Kesselheim
Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs. BMJ medicine 1 (1) (2022)
Mayookha Mitra-Majumdar, Aaron S Kesselheim
Reporting bias in clinical trials: Progress toward transparency and next steps. PLoS medicine 19 (1) (2022)
Kimberly Feng, Aaron S Kesselheim, Massimiliano Russo, Benjamin N Rome
Patient Out-of-Pocket Costs Following the Availability of Biosimilar Versions of Infliximab. Clinical pharmacology and therapeutics (2022)
Hussain S Lalani, Aaron S Kesselheim, Benjamin N Rome
Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company. Annals of internal medicine 175 (7) (2022)
Avi Cherla, Elias Mossialos, Maximilian Salcher-Konrad, Aaron S Kesselheim, Huseyin Naci
Post-Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004-2014. Clinical pharmacology and therapeutics 112 (4) (2022)
Leah Zoe Gibson Rand, G J Melendez-Torres, Aaron S Kesselheim
Alternatives to the quality-adjusted life year: How well do they address common criticisms? Health services research 58 (2) (2022)
VÉronique C Raimond, William B Feldman, Benjamin N Rome, Aaron S Kesselheim
Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation. The Milbank quarterly 99 (1) (2021)
Spencer Phillips Hey, Cory V Gerlach, Garrett S Dunlap, Vinay Prasad, Aaron S Kesselheim
The evidence landscape in precision medicine. Science translational medicine 12 (540) (2021)
Benjamin N Rome, ChangWon C Lee, Aaron S Kesselheim
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018. Clinical pharmacology and therapeutics 109 (2) (2020)
Kueiyu Joshua Lin, Evan Dvorin, Aaron S Kesselheim
Prescribing systemic steroids for acute respiratory tract infections in United States outpatient settings: A nationwide population-based cohort study. PLoS medicine 17 (3) (2020)
Aaron S Kesselheim, Michael S Sinha, Eric G Campbell, Sebastian Schneeweiss, Paula Rausch, Brian M Lappin, Esther H Zhou, Jerry Avorn, Gerald J Dal Pan
Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug safety 42 (11) (2020)
Ameet Sarpatwari, Jonathan DiBello, Marie Zakarian, Mehdi Najafzadeh, Aaron S Kesselheim
Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS medicine 16 (7) (2019)
Rahul K Nayak, Jerry Avorn, Aaron S Kesselheim
Public sector financial support for late stage discovery of new drugs in the United States: cohort study. BMJ (Clinical research ed.) 367 (2019)
Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John G Connolly, Michael A Fischer, Aaron S Kesselheim, Joshua J Gagne
Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS medicine 16 (3) (2019)
Bishal Gyawali, Aaron S Kesselheim
Reinforcing the social compromise of accelerated approval. Nature reviews. Clinical oncology 15 (10) (2019)
Michael Fralick, Sebastian G Schneeweiss, Christopher J D Wallis, Emily H Jung, Aaron S Kesselheim
Desmopressin and the risk of hyponatremia: A population-based cohort study. PLoS medicine 16 (10) (2019)
Michael S Sinha, Aaron S Kesselheim
The next forum for unraveling FDA off-label marketing rules: State and federal legislatures. PLoS medicine 15 (5) (2018)
Michael S Sinha, Clark C Freifeld, John S Brownstein, Macarius M Donneyong, Paula Rausch, Brian M Lappin, Esther H Zhou, Gerald J Dal Pan, Ajinkya M Pawar, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim
Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR public health and surveillance 4 (1) (2018)
Aaron S Kesselheim, Macarius Donneyong, Gerald J Dal Pan, Esther H Zhou, Jerry Avorn, Sebastian Schneeweiss, John D Seeger
Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiology and drug safety 26 (6) (2017)
Aaron S Kesselheim, Carolyn L Treasure, Barbara Koenig
Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS medicine 14 (1) (2017)